Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2021-10-05 Director's Dealing
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2021-10-05 English
FORM 4
Director's Dealing
2021-10-05 English
FORM 4
Director's Dealing
2021-10-05 English
FORM 4
Director's Dealing
2021-10-05 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 21, 2021, for Cidara Therapeutics, Inc. It reports an event under Item 8.01 'Other Events' describing a presentation at the company's Research and Development Day via webinar. The presentation slides are attached as Exhibit 99.1. The document does not contain financial statements or detailed financial data but rather announces the occurrence of a corporate presentation event and includes the presentation as an exhibit. The length of the document is 3103 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, such a document is best classified as an Investor Presentation (IP) because it focuses on a detailed presentation for investors about company strategy and R&D, rather than a full financial report or other filing types.
2021-09-21 English
FORM 4
Director's Dealing
2021-09-15 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.